Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.19.3.a.u2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 01, 2018
USD ($)
Jun. 01, 2017
USD ($)
Feb. 01, 2012
USD ($)
Oct. 10, 2001
USD ($)
shares
Dec. 31, 2005
USD ($)
Feb. 28, 2019
USD ($)
May 31, 2019
USD ($)
Nov. 30, 2019
USD ($)
CompensationPlan
Unit
shares
Nov. 30, 2018
USD ($)
Debt Securities, Available-for-sale [Line Items]                  
ASC 606 adoption adjustment, net of tax               $ 253,447  
Cumulative effect on retained earnings, tax               94,192  
Deferred revenue               32,508,511  
Deferred revenue current               8,875,138  
Warranty payment   $ 100,000 $ 75,000   $ 50,000        
Offset personal expenses   10,000              
Commission paid               35,300  
Capitalized contract acquisition costs, net of amortization expense $ 329,231                
Cumulative amortization expense 66,533                
Additional capitalized contract acquisition costs, net of amortization expense               87,518  
Provisions for interest or penalties related to uncertain tax positions               0 $ 0
Uncertain tax provisions               0 0
Impairment on long lived assets               $ 0 0
Number of employee stock based compensation plan | CompensationPlan               2  
Unrealized holding gains, trading securities                 28,000
Cumulative-effect adjustment from accumulated other comprehensive income to retained earnings           $ 341,000      
Unrealized holding gain (losses), marketable securities               $ 28,000 300,000
Payment warranty         $ 50,000        
Increased payment warranty   $ 100,000 75,000            
Additional payment warranty     $ 10,000            
Stock compensation expense reversed               $ 444,000  
Stock compensation, number of shares opted to lump sum cash payment | shares               30,000  
Impairment charges             $ 2,332,763 $ 2,332,763  
Concentration risk related to supplier               The Company depends on one supplier for the source of its collection kits  
Advertising cost included in selling, general and administrative expenses               $ 981,448 986,664
Stock-based option compensation expense               $ 398,000 $ 478,000
Deferred revenue recognition period               12 months  
Employee Stock Incentive Plan [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Number of outstanding options excluded from computation of diluted earnings per share | shares               70,136  
Saneron [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Ownership interest               33.00% 33.00%
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Non-Controlling interest after merger       43.42%          
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares       260,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary       $ 1,924,000          
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary | shares       195,000          
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary       $ 3,900          
Accounting Standards Update 2014-09 [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Incremental contract acquisition cost 329,231                
Reversed incremental acquisition cost 18,408                
ASC 606 adoption adjustment, net of tax 253,447                
Cumulative effect on retained earnings, tax $ 94,192                
Option One [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Contracted storage amortization period               21 years  
Option Two [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Contracted storage amortization period               1 year  
Option Three [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Contracted storage amortization period               life-time  
Contracted storage amortization description               The life-time storage plan is based on a life expectancy of 81 years, which is the current estimate by the Center for Disease Control for United States women’s life expectancy and concluded that additional data analysis would result in an immaterial difference in revenue  
Accounts Receivables [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Period of doubtful for accounts receivable due from client               30 days  
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Inventory, in units | Unit               6,000  
Number of units, per month | Unit               12  
Umbilical Cord Blood and Cord Tissue Stem Cell Service and PrepaCyte-CB [Member] | Duke University [Member] | Maximum [Member]                  
Debt Securities, Available-for-sale [Line Items]                  
Inventory, in units | Unit               144